Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
64 studies found for:    burzynski
Show Display Options
Rank Status Study
21 Unknown  Antineoplaston Therapy in Treating Patients With Stage IV Bladder Cancer or Stage IV Newly Diagnosed, Incurable Bladder Cancer
Condition: Bladder Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
22 Active, not recruiting A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)
Condition: Diffuse, Intrinsic Pontine Glioma
Intervention: Drug: Antineoplaston therapy (Atengenal + Astugenal)
23 Completed
Has Results
Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors
Condition: Childhood CNS Primitive Neuroectodermal Tumor
Intervention: Drug: Antineoplaston therapy (Atengenal + Astugenal)
24 Terminated Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma
Condition: CNS Tumor
Intervention: Drug: Antineoplaston therapy (Atengenal + Astugenal)
25 Withdrawn Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer
Conditions: Stage IV Breast Cancer;   Recurrent Breast Cancer
Interventions: Drug: antineoplaston A10;   Drug: methotrexate;   Procedure: alternative product therapy;   Procedure: biological therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: chemotherapy;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy
26 Unknown  Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
27 Unknown  Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
28 Unknown  Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
29 Unknown  Antineoplaston Therapy in Treating Patients With Primary Liver Cancer
Condition: Liver Cancer
Intervention: Drug: antineoplaston A10
30 Unknown  Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva
Conditions: Cervical Cancer;   Vulvar Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
31 Unknown  Antineoplaston Therapy in Treating Patients With Stomach Cancer
Condition: Gastric Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
32 Unknown  Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine
Condition: Small Intestine Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
33 Unknown  Antineoplaston Therapy in Treating Patients With Soft Tissue Sarcoma
Condition: Sarcoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
34 Unknown  Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer
Conditions: Kidney Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
35 Withdrawn Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Stage III Prostate Cancer;   Stage IV Prostate Cancer;   Recurrent Prostate Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Drug: bicalutamide;   Drug: flutamide;   Drug: leuprolide acetate;   Procedure: alternative product therapy;   Procedure: antiandrogen therapy;   Procedure: biological therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy;   Procedure: endocrine therapy;   Procedure: hormone therapy
36 Unknown  Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
37 Unknown  Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors
Condition: Sarcoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
38 Withdrawn Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
Conditions: Merkel Cell Carcinoma;   Islet Cell Carcinoma;   Neuroendocrine Carcinoma;   Pituitary Tumor
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Procedure: alternative product therapy;   Procedure: biological therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy
39 Unknown  Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
40 Unknown  Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia
Conditions: Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.